Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
The Scynexis Inc. company patent portfolio operates within the Biotechnology & Pharmaceuticals technology area. Prosecution data shows 2 pending office actions, which are distributed across 2 distinct examiners and 2 distinct art units. This distribution indicates that the company is pursuing multiple technical paths or distinct innovations simultaneously within the Biotechnology & Pharmaceuticals field.
The busiest examiner for this portfolio is GALSTER, SAMUEL LEONARD, who is currently overseeing 1 busiest examiner pending office action. Given that there are 2 pending office actions in total, the workload is split, with GALSTER, SAMUEL LEONARD handling a portion of the active prosecution. The involvement of 2 distinct art units suggests that the applications cover different sub-sectors of the industry.
Practitioners can observe that the prosecution is not centralized under an individual examiner, as there are 2 distinct examiners involved. With 2 pending office actions active, the company maintains a steady but diversified presence in the patent office. The balance between 2 distinct examiners and 2 distinct art units reflects a broad approach to securing intellectual property while spreading risk across different examination groups.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (33%) |
| Double-patenting + other | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OTTON, ALICIA L | 1 | 65.0% | +9.3% |
| GALSTER, SAMUEL LEONARD | 1 | 52.1% | +42.2% |
| LEE, WILLIAM Y | 1 | 48.0% | +34.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17610440 | ANTIFUNGAL AGENTS FOR CANDIDA AURIS DECOLONIZATION | GALSTER, SAMUEL LEONARD | — |
| 17399015 | ANTIFUNGAL AGENTS USED IN COMBINATION | LEE, WILLIAM Y | — |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| 1693 | 1 |
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18967641 | ANTIFUNGAL AGENTS WITH ENHANCED ACTIVITY IN ACIDIC PH | OTTON, ALICIA L | 1629 | §102DP | Non-Final OA | — | Pending | Dec 03, 2024 |
| 17610440 | ANTIFUNGAL AGENTS FOR CANDIDA AURIS DECOLONIZATION | GALSTER, SAMUEL LEONARD | 1693 | §103DP | Final Rejection | — | Pending | Nov 10, 2021 |
| 17399015 | ANTIFUNGAL AGENTS USED IN COMBINATION | LEE, WILLIAM Y | 1623 | DP | Final Rejection | — | Pending | Aug 10, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialScynexis Inc. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Alicia L Otton has the most, with 1 of Scynexis Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
